Figure 4: Chronic administration of P5 improves glycaemic status in diabetic mice.
From: Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Effect on food intake (a), body weight (b), fat mass (c), ad libitum-fed plasma glucose (d) and insulin (e) levels following daily subcutaneous injection of saline (black), Ex4 (blue) and P5 (orange) at 10 μg kg−1 in ob/ob mice. (f–h) Effect of 10 μg kg−1 (f,h; darker shade) and 1 μg kg−1 (g,h; lighter shade) of P5 or Ex4 on intraperitoneal glucose tolerance following daily subcutaneous injection of saline (black), Ex4 (blue) and P5 (orange) in DIO mice. (n=8). Effect of P5 or Ex4 on ad libitum-fed plasma glucose level (i), HbA1C (j), insulin plasma level (k), islet morphology (l) after daily subcutaneous injections of saline (black), Ex4 (blue) and P5 (orange) at 1 μg kg−1 (lighter shade) or 10 μg kg−1 (darker shade) (n=6–8). Scale bar, 20 μm. Data are mean±s.e.m. Statistic by two-tailed t-test: *P<0.05; **P<0.01, comparing saline to peptide injection. AUC, area under the curve.
